Clinical Trials Directory

Trials / Unknown

UnknownNCT02982148

Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients

Comparison Between Intradermal Injection and Subcutaneous Injection With Methylene Blue for Sentinel Lymph Node Biopsy for Breast Cancer Patients

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
352 (estimated)
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is designed to compare the effectiveness of intradermal injection and subcutaneous injection with methylene blue for early-stage breast cancer patients who need sentinel lymph node biopsy.

Detailed description

After fully informing and consent, patients recruited would be randomized 1:1 to intradermal injection group and subcutaneous injection group. Investigators aimed to find out the difference in sentinel lymph nodes detected rate, blue lymphatic detected rate and complication incidence between the two groups.

Conditions

Interventions

TypeNameDescription
DEVICEmethylene blue intradermal injectionMethylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
DEVICEmethylene blue subcutaneous injectionMethylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.

Timeline

Start date
2015-05-01
Primary completion
2017-01-01
Completion
2017-01-01
First posted
2016-12-05
Last updated
2016-12-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02982148. Inclusion in this directory is not an endorsement.